Investigation of SCUBE-1 levels in pediatric patients with beta-thalassemia

Can Acıpayam; Defne Ay Tuncel; Hatice Güneş; Behiye Nurten Seringeç Akkeçeci; Fatma İnanç Tolun; Sevcan İpek; Ömer Duyuran

doi:10.28982/josam.653402

Authors

Can Acıpayam https://orcid.org/0000-0002-6379-224X
Defne Ay Tuncel https://orcid.org/0000-0002-1262-8271
Hatice Güneş https://orcid.org/0000-0002-6940-0964
Behiye Nurten Seringeç Akkeçeci Kahramanmaraş Sütçü İmam Üniversitesi Fizyoloji Bilimdalı https://orcid.org/0000-0003-1915-2350
Fatma İnanç Tolun https://orcid.org/0000-0002-1157-2958
Sevcan İpek https://orcid.org/0000-0002-1406-4895
Ömer Duyuran https://orcid.org/0000-0003-3087-0587

DOI:

https://doi.org/10.28982/josam.653402

Keywords:

Beta-thalassemia major, Children, SCUBE-1, Thrombosis

Abstract

Aim: A thrombosis and inflammation marker, Signal peptide-CUB (complement C1r/C1 s)-EGF (epidermal growth factor)-like domain-containing protein 1 (SCUBE-1) is expressed in endothelial cells and activated platelets. We aimed to investigate the levels of this marker in patients with Thalassemia major (TM), a disease which causes a tendency to thrombosis.

Methods: Twenty patients with TM and age and gender-matched twenty healthy controls were included in this prospective case-control study. Other thrombosis markers such as D-dimer and homocysteine were studied in addition to SCUBE-1 in both groups.

Results: The SCUBE1 and D-dimer levels were higher in the TM group compared to the control group (P=0.004, P=0.023, respectively). A significant positive correlation was detected between platelet count and SCUBE1 (r=0.342, P=0.031).

Conclusion: We detected elevated SCUBE1 levels in children with TM compared to the healthy controls, which correlated with platelet count. SCUBE1 may be used as a thrombosis marker in TM in the early stages of the disease.

Downloads

Download data is not yet available.

References

Sirachainan N. Thalassemia and the hypercoagulable state. Thromb Res. 2013;132:637-41. doi: 10.1016/j.thromres.2013.09.029.

Akar N, Kemahli S, Uysal Z, Cin S. Thromboembolism in beta-thalassemia major. Acta Haematol. 1998;100:166. doi: 10.1159/000040897.

Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36-43. doi: 10.1182/blood.v99.1.36.

Garofoli F, Ciardelli L, Mazzucchelli I, Borghesi A, Angelini M, Bollani L, et al. The red cell distribution width (RDW): value and role in preterm, IUGR (intrauterine growth restricted), full-term infants. Hematology. 2014;19:365-9. doi: 10.1179/1607845413Y.0000000141.

Karagüzel E, Menteşe A, Kazaz İO, Demir S, Örem A, Okatan AE, et al. SCUBE1: a promising biomarker in renal cell cancer. Int Braz J Urol. 2017;43:638-643. doi: 10.1590/S1677-5538.IBJU.2016.0316.

Bolayır HA, Güneş H, Kıvrak T, Şahin Ö, Akaslan D, Kurt R, et al. The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction. Anatol J Cardiol. 2017;18:122-7. doi: 10.14744/AnatolJCardiol.2017.7705.

Lindemann S, Gawaz M. SCUBE1-a new scoop in vascular biology? Cardiovasc Res. 2006;71:414-5. doi: 10.1016/j.cardiores.2006.06.005.

Tu CF, Su YH, Huang YN, Tsai MT, Li LT, Chen YL, et al. Localization and characterization of a novel secreted protein SCUBE1 in human platelets. Cardiovasc Res. 2006;71:486-95. doi: 10.1016/j.cardiores.2006.04.010.

Peacock WF. Will SCUBE1 solve the ischemia marker deficit? J Am Coll Cardiol. 2008;51:2181-3. doi: 10.1016/j.jacc.2008.02.060.

Ercan M, Mungan S, Güzel I, Celik HT, Bal C, Abusoglu S, et al. Serum asymmetric dimethylarginine and nitric oxide levels in Turkish patients with acute ischemic stroke. Adv Clin Exp Med. 2019;28:693-8. doi:10.17219/acem/78360.

Chow S C, Shao J, Wang H. A note on sample size calculation for mean comparisons based on noncental t-statistics. Journal of Biopharmaceutical Statistics. 2002;12:441-56.

Uyanikoglu H, Hilali NG, Yardimciel M, Koyuncu I. A new biomarker for the early diagnosis of ovarian torsion: SCUBE-1. Clin Exp Reprod Med. 2018;45:94-9. doi: 10.5653/cerm.2018.45.2.94.

Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, et al. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br J Haematol. 1999;107:739-46. doi: 10.1046/j.1365-2141.1999.01758.

Menichelli A, Cianciulli P, Gaviano E, Trua G, Papa G, Giulio S, et al. Platelet activation in thalassemic Children. Pediatric Research. 1991;30:646.

Koçak MZ, Dağlı M, Fidan K. Assessment of risk factors affecting thrombosis in patients with essential thrombocytosis. J Surg Med. 2018;2(2):46-9. doi: 10.28982/josam.396881.

Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in â thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood. 1991;77:1749-53.

Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/β-Thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77:299-303. doi: 10.1007/bf02983790.

Gunaydın M, Turkmen S, Sahin A, Sumer A, Mentese A, Turedi S, et al. The diagnostic value of SCUBE1 levels in acute ischemic stroke. Turk J Biochem. 2014;39:10712.

Tu CF, Yan YT, Wu SY, Djoko B, Tsai MT, Cheng CJ, et al. Domain and functional analysis of a novel platelet-endothelial cell surface protein, SCUBE1. J Biol Chem. 2008;283:12478-88. doi: 10.1074/jbc.M705872200.

Özkan G, Ulusoy S, Menteşe A, Karahan SC, Cansiz M. New marker of platelet activation, SCUBE1, is elevated in hypertensive patients. Am J Hypertens. 2013;26:748-53. doi: 10.1093/ajh/hpt007.

Dai DF, Thajeb P, Tu CF, Chiang FT, Chen CH, Yang RB, et al. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. J Am Coll Cardiol. 2008;51:2173-80 doi: 10.1016/j.jacc.2008.01.060.

Turkmen S, Mentese S, Mentese A, Sumer AU, Saglam K, Yulug E, et al. The value of signal peptide-CUB-EGF domain-containing protein 1 and oxidative stress parameters in the diagnosis of acute mesenteric ischemia. Acad Emerg Med. 2013;20:257-64. doi: 10.1111/acem.12096.

Bolayır A, Gökçe ŞF, Çiğdem B, Bolayır HA, Gülünay A, Çelik VK, et al. Can SCUBE1 be used to predict the early diagnosis, lesion volume and prognosis of acute ischemic stroke? Turk J Biochem. 2018;44:16-24.

Bolayır HA, Kıvrak T, Güneş H, Akaslan D, Şahin Ö, Bolayır A. The role of SCUBE1 in the development of late stent thrombosis presenting with ST-elevation myocardial infarction. Rev Port Cardioli. 2018;37:375-81. doi: 10.1016/j.repc.2017.07.015.

Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Davì G. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost. 2012;108:1109–23. doi: 10.1160/TH12-08-0550.

Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58. doi: 10.2174/138161211795049804.

Cikrikcioglu MA, Celik K, Ekinci I, Nasifov M, Toprak AE, Cetin G, et al. Mean Platelet Volume in Heterozygous Beta Thalassaemia. Acta Haematol. 2017;137:100-5. doi: 10.1159/000455813.